ACUTA CAPITAL PARTNERS, LLC - Q1 2020 holdings

$206 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 32 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 51.7% .

 Value Shares↓ Weighting
AXSM SellAXSOME THERAPEUTICS INC$18,149,000
-71.1%
308,500
-49.2%
8.80%
-43.4%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$11,959,000
-34.2%
399,500
-39.1%
5.80%
+28.8%
ARVN SellARVINAS INC$11,289,000
-22.8%
280,120
-21.3%
5.47%
+51.0%
AUPH SellAURINIA PHARMACEUTICALS INC$11,173,000
-47.9%
770,000
-27.2%
5.42%
+2.1%
KDMN SellKADMON HLDGS INC$9,888,000
-63.9%
2,360,000
-60.9%
4.79%
-29.3%
XENE SellXENON PHARMACEUTICALS INC$7,127,000
-40.7%
628,500
-31.5%
3.45%
+15.9%
DRNA SellDICERNA PHARMACEUTICALS INC$4,712,000
-44.8%
256,500
-33.8%
2.28%
+8.0%
CNST SellCONSTELLATION PHARMCETICLS I$4,383,000
-52.9%
139,464
-29.4%
2.12%
-7.8%
RETA SellREATA PHARMACEUTICALS INCcl a$3,392,000
-56.3%
23,500
-38.2%
1.64%
-14.6%
APLT SellAPPLIED THERAPEUTICS INC$3,334,000
-17.4%
102,000
-31.1%
1.62%
+61.6%
ARWR SellARROWHEAD PHARMACEUTICALS IN$3,156,000
-88.8%
109,700
-75.2%
1.53%
-78.0%
KURA SellKURA ONCOLOGY INC$1,970,000
-40.3%
198,000
-17.5%
0.96%
+16.9%
BCRX SellBIOCRYST PHARMACEUTICALS$500,000
-94.9%
250,000
-91.2%
0.24%
-90.0%
ISEE SellIVERIC BIO INC$478,000
-93.9%
139,000
-84.7%
0.23%
-88.0%
XFOR ExitX4 PHARMACEUTICALS INC$0-40,000
-100.0%
-0.11%
ADVM ExitADVERUM BIOTECHNOLOGIES INCcall$0-100,000
-100.0%
-0.28%
CCXI ExitCHEMOCENTRYX INC$0-35,000
-100.0%
-0.34%
ACST ExitACASTI PHARMA INCcl a new$0-620,000
-100.0%
-0.38%
MDCO ExitMEDICINES CO$0-21,700
-100.0%
-0.46%
KALV ExitKALVISTA PHARMACEUTICALS INC$0-107,500
-100.0%
-0.47%
IMMU ExitIMMUNOMEDICS INC$0-150,000
-100.0%
-0.79%
ZYME ExitZYMEWORKS INC$0-70,500
-100.0%
-0.79%
ITCI ExitINTRA CELLULAR THERAPIES INCcall$0-100,000
-100.0%
-0.85%
INSM ExitINSMED INC$0-169,000
-100.0%
-1.00%
NLTX ExitNEOLEUKIN THERAPEUTICS INC$0-372,500
-100.0%
-1.14%
MIST ExitMILESTONE PHARMACEUTICALS IN$0-508,500
-100.0%
-2.02%
KPTI ExitKARYOPHARM THERAPEUTICS INC$0-590,000
-100.0%
-2.80%
ITCI ExitINTRA CELLULAR THERAPIES INC$0-587,089
-100.0%
-4.99%
XBI ExitSPDR SERIES TRUSTput$0-500,000
-100.0%
-11.78%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
IOVANCE BIOTHERAPEUTICS INC24Q1 202321.2%
IRIDEX CORP20Q3 20198.1%
ARROWHEAD PHARMACEUTICALS INC20Q2 20237.9%
IMMUNOMEDICS INC19Q3 202020.6%
VERACYTE INC19Q3 201910.1%
ASCENDIS PHARMA A S18Q2 20207.2%
XENON PHARMACEUTICALS INC18Q3 20224.6%
CAS MED SYS PAR $0.00418Q1 20196.4%
APELLIS PHARMACEUTICALS INC17Q3 202318.4%
KURA ONCOLOGY INC. COMMON STOCK17Q3 20238.1%

View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ACUTA CAPITAL PARTNERS, LLC Q1 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
BCLS Acquisition Corp.Sold outFebruary 14, 202300.0%
Jiya Acquisition Corp.Sold outFebruary 14, 202300.0%
VistaGen Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Larimar Therapeutics, Inc.Sold outFebruary 15, 202200.0%
CATALYST BIOSCIENCES, INC.Sold outFebruary 14, 202200.0%
Aadi Bioscience, Inc.September 07, 20211,529,4027.2%
Kadmon Holdings, Inc.February 14, 20207,373,3334.6%
IRIDEX CORPSold outNovember 13, 201900.0%
ASSEMBLY BIOSCIENCES, INC.February 14, 2019718,5002.8%
CAS MEDICAL SYSTEMS INCFebruary 14, 20195,263,50818.2%

View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14
13F-HR2023-02-14
13F-HR2022-11-14

View ACUTA CAPITAL PARTNERS, LLC's complete filings history.

Compare quarters

Export ACUTA CAPITAL PARTNERS, LLC's holdings